SB 2244 SD-1

RELATING TO WORKERS' COMPENSATION

A BILL FOR AN ACT

RELATING TO WORKERS' COMPENSATION.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

- 1 SECTION 1. The legislature finds that drug overdose deaths
- 2 and opioid-involved deaths continue to increase in the United
- 3 States. According to information from the federal Centers for
- 4 Disease Control and Prevention, the majority of drug overdose
- 5 deaths involve an opioid. The number of overdose deaths
- 6 involving opioids has quadrupled since 1999, with more than half
- 7 a million people dying from drug overdoses between 2000 and
- 8 2015. The Centers for Disease Control and Prevention notes that
- 9 overdoses from prescription opioids are a driving factor in the
- 10 fifteen-year increase in opioid overdose deaths. Furthermore,
- 11 although the amount of prescription opioids sold to pharmacies,
- 12 hospitals, and doctors' offices nearly quadrupled from 1999 to
- 13 2010, there has not been an overall change in the amount of pain
- 14 reported by Americans. The Centers for Disease Control and
- 15 Prevention also estimates that the total economic burden of
- 16 prescription opioid misuse in the United States is
- 17 \$78,500,000,000 a year, including the costs of health care, lost

- 1 productivity, addiction treatment, and criminal justice
- 2 involvement.
- 3 The legislature further finds that numerous efforts have
- 4 been made at the national and state levels to respond to the
- 5 nation's opioid epidemic. A number of states have also taken
- 6 steps through their workers' compensation systems to stem the
- 7 overprescribing of opioids to workers injured on the job.
- 8 The use of prescription opioids may be a reasonable and
- 9 appropriate treatment option for some workplace injuries.
- 10 However, the legislature notes that according to the National
- 11 Safety Council, research on medical outcomes when opioids are
- 12 used in workers' compensation has demonstrated that opioid use
- 13 beyond the acute phase can impair function, be a barrier to
- 14 recovery, and increase an injured worker's experience of pain.
- 15 The legislature therefore finds that it is important to
- 16 address the opioid epidemic in the workers' compensation system
- 17 in a manner similar to the way opioid use has been addressed in
- 18 other areas of state law.
- 19 Accordingly, the purpose of this Act is to:
- 20 (1) Require health care providers in the workers'
- 21 compensation system who are authorized to prescribe

1	opioids to adopt and maintain policies for informed				
2	consent to opioid therapy in circumstances that carry				
3	elevated risk of dependency; and				
4	(2) Establish limits for concurrent opioid and				
5	benzodiazepine prescriptions in the workers'				
6	compensation system.				
7	SECTION 2. Chapter 386, Hawaii Revised Statutes, is				
8	amended by adding two new sections to be appropriately				
9	designated and to read as follows:				
10	"§386-A Opioid therapy; qualifying injured employees;				
11	informed consent process. (a) Beginning on July 1, 2019, any				
12	health care provider authorized to prescribe opioids shall adopt				
13	and maintain a written policy or policies that include execution				
14	of a written agreement to engage in an informed consent process				
15	between the health care provider authorized to prescribe opioids				
16	and a qualifying injured employee.				
17	(b) The department shall make available on its website a				
18	copy of the template developed by the department of health				
19	pursuant to section 329-38.5(b). The template shall be posted				
20	to the department's website no later than December 31, 2018.				

1	(c)	For the purposes of this section, "qualifying injured				
2	employee" means:					
3	(1) An injured employee requiring opioid treatment for					
4		more than three months;				
5	(2)	An injured employee who is prescribed benzodiazepines				
6		and opioids together; or				
7	(3)	An injured employee who is prescribed a dose of				
8		opioids that exceeds ninety morphine equivalent doses.				
9	(d)	A violation of this section shall not be subject to				
10	the penalty provisions of part IV of chapter 329.					
11	§386-B Qualifying injured employees; initial concurrent					
12	prescriptions; opioids and benzodiazepines. (a) Initial					
13	concurrent prescriptions for opioids and benzodiazepines shall					
14	not be for	not be for longer than seven consecutive days unless a supply of				
15	longer than seven days is determined to be reasonably needed for					
16	the treat	the treatment of:				
17	(1)	Pain experienced while the qualifying injured employee				
18	i i i	is in post-operative care;				
19	(2)	Chronic pain and pain management;				
20	(3)	Substance abuse or opioid or opiate dependence;				
21	(4)	Cancer;				

1	(5) Pain experienced while the qualifying injured employee					
2	is in palliative care; or					
3	(6) Pain experienced while the qualifying injured employee					
4	is in hospice care;					
5	provided that if a health care provider authorized to prescribe					
6	opioids issues a concurrent prescription for more than a seven-					
7	day supply of an opioid and benzodiazepine, the health care					
8	provider shall document in the qualifying injured employee's					
9	medical record the condition for which the health care provider					
10	issued the prescription and that an alternative to the opioid					
11	and benzodiazepine was not appropriate treatment for the					
12	condition.					
13	(b) After an initial concurrent prescription for opioids					
14	and benzodiazepines has been made, a health care provider					
15	authorized to prescribe opioids may authorize subsequent					
16	prescriptions through a telephone consultation with the					
17	qualifying injured employee when the health care provider deems					
18	such action to be reasonably needed for post-operative care and					
19	pain management; provided that the health care provider shall					
20	consult with a qualifying injured employee in person at least					
21	once every ninety days for the duration during which the health					

- 1 care provider concurrently prescribes opioids and
- 2 benzodiazepines to the qualifying injured employee.
- 3 (c) For the purposes of this section, "qualifying injured
- 4 employee" has the same meaning as in section 386-A."
- 5 SECTION 3. Section 386-21.7, Hawaii Revised Statutes, is
- 6 amended by amending subsection (a) to read as follows:
- 7 "(a) Notwithstanding any other provision to the contrary,
- 8 immediately after a work injury is sustained by an employee and
- 9 so long as reasonably needed, the employer shall furnish to the
- 10 employee all prescription drugs as the nature of the injury
- 11 requires [-]; provided that initial concurrent prescriptions for
- 12 opioids and benzodiazepines shall meet the requirements of
- 13 section 386-B. The liability for the prescription drugs shall
- 14 be subject to the deductible under section 386-100."
- 15 SECTION 4. In codifying the new sections added by
- 16 section 2 of this Act, the revisor of statutes shall substitute
- 17 appropriate section numbers for the letters used in designating
- 18 the new sections in this Act.
- 19 SECTION 5. Statutory material to be repealed is bracketed
- 20 and stricken. New statutory material is underscored.

21

1 SECTION 6. This Act shall take effect on January 1, 2045.

Report Title:

Workers' Compensation; Opioid Therapy; Informed Consent; Prescription Limits

Description:

Requires health care providers in the workers' compensation system who are authorized to prescribe opioids to adopt and maintain policies for informed consent to opioid therapy in circumstances that carry elevated risk of dependency. Establishes limits for concurrent opioid and benzodiazepine prescriptions. Takes effect 1/1/2045. (SD1)

The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.

SB 2244 SD-1

TESTIMONY

DOUGLAS S. CHIN



STATE OF HAWAII DEPARTMENT OF LABOR AND INDUSTRIAL RELATIONS

830 PUNCHBOWL STREET, ROOM 321 HONOLULU, HAWAII 96813

www.labor.hawaii.gov Phone: (808) 586-8844 / Fax: (808) 586-9099 Email: dlir.director@hawaii.gov

March 22, 2018

To: The Honorable Aaron Ling Johanson, Chair,

The Honorable Daniel Holt, Vice Chair, and

Members of the House Committee on Labor and Public Employment

The Honorable John M. Mizuno, Chair,

The Honorable Bertrand Kobayashi, Vice Chair and

Members of the House Committee on Health and Human Services

Date: Thursday, March 22, 2018

Time: 8:30 a.m.

Place: Conference Room 309, State Capitol

From: Leonard Hoshijo, Director

Department of Labor and Industrial Relations (DLIR)

Re: S.B. No. 2244 SD1 RELATING TO WORKERS' COMPENSATION

I. OVERVIEW OF PROPOSED LEGISLATION

SB2244SD1 proposes two new sections for Chapter 386, Hawaii Revised Statutes (HRS) The first under section **386-A** titled "**Opioid therapy**; **qualifying injured employees**; **informed consent process**", which will require an opioid therapy consent process agreement between the injured employee and the physician who prescribes the opioid(s). The written agreement will at the minimum consists of specific requirements on the part of both the injured employee and the physician.

The second proposed section **386-B**, titled "Qualifying injured employees; initial concurrent prescriptions; opioids and benzodiazepines" will limit the initial prescription to no more than a seven-day supply.

Section 3 of this proposal also amends Section 386-21.7, HRS, by amending subsection (a) to ensure that the initial concurrent prescriptions of opioids and benzodiazepines meet the requirement of the proposed section 386-B.

The Department <u>supports the intent</u> of the measure and suggests amendments are needed to address potential unintended consequences.

II. CURRENT LAW

Currently, nothing in Chapter 386, HRS, mandates a consent process agreement be made between the injured employee and the prescribing physician of opioid drugs. Section 386-21.7, HRS, specifies how prescription and compound drugs are reimbursed. The law does not specify limits on supply for compound drugs and does not preclude the physician from dispensing any drug including schedule II drugs beyond thirty days.

III. COMMENTS ON THE SENATE BILL

DLIR <u>supports the intent</u> of the measure; however, it suggests amendments are needed for the measure to address potential, unintended consequences.

Section 1 of this proposal mandates a consent process agreement between the injured employee and the prescribing physician. If the parties do not enter into an agreement prior to the prescribing of opioid drugs, will the employer have the right to deny the injured employee the prescribed opioid drugs? If the employer did deny, the injured worker would need to request a hearing, essentially defeating the purpose of the prescription as the injured worker would not have the medication to treat the pain through workers' compensation.

Another unintended consequence could involve creating another basis for the parties to enter into a bill dispute process. The number of bill disputes has dropped from approximately 2,200 in 2013 to under 200 currently. This has allowed the hearings branch to focus on other matters and has helped to significantly reduced the backlog of hearings, which benefits all parties in the workers' compensation program.

DLIR supports the concept of a consent agreement process to help ensure that schedule II drugs, which have a high potential for abuse, are prescribed based upon medical necessity and are justifiably reasonable and necessary. According to the Centers for Disease Control and Prevention, "Opioids (including prescription opioids and heroin) killed more than 33,000 people in 2015, more than any year on record. Nearly half of all opioid overdose deaths involve a prescription opioid." The opioid epidemic in the United States has a far-reaching impact on the workers compensation system. Many injured workers are prescribed opioid drugs to help with pain following a serious injury. For Service Year 2016, Hawaii spent \$8 million on 57,000 prescriptions for workers compensation claims.

If an injured worker becomes addicted to his or her "pain meds," it greatly affects their ability to get back to work, may increase their disability which will lead to higher medical costs, and sadly can have a disabling effect on the injured worker's family relationships and finances. This proposal limits the initial concurrent prescriptions of opioids and benzodiazepines to a seven (7) day supply. We support this as it will still provide the injured employee with the needed immediate relief.



STATE OF HAWAII DEPARTMENT OF HEALTH

P. O. Box 3378 Honolulu, HI 96801-3378 doh.testimony@doh.hawaii.gov

Testimony COMMENTING on SB 2244 SD1 RELATING TO WORKERS' COMPENSATION

REPRESENTATIVE AARON LING JOHANSON, CHAIR HOUSE COMMITTEE ON LABOR & PUBLIC EMPLOYMENT

REPRESENTATIVE JOHN M. MIZUNO, CHAIR HOUSE COMMITTEE ON HEALTH & HUMAN SERVICES

Hearing Date: March 22, 2018 Room Number: 309

- 1 Fiscal Implications: Undetermined
- 2 **Department Testimony:** The Department of Health (DOH) supports the intent of this bill to
- 3 require providers to adopt an informed consent for injured employees requiring opioid therapy,
- 4 as well as the regulation of initial concurrent prescriptions for opioids and benzodiazepines. This
- 5 measure aligns with the following objectives in the Hawaii Opioid Action Plan (Plan), developed
- 6 by the Governor's Opioid and Substance Misuse Initiative (Collaborative):
- Objective 2-3: By March 2018, engage payers and physician organizations to
 disseminate basic best practice information on opioid-prescribing statewide;
- Objective 2-3a: By December 2019, develop a standardized training on opioid prescribing best practices and provide training to 50 percent of prescribers statewide; and
- Objective 2-4: By July 2018, implement informed consent template as outlined in Act 66
 (2017).
- The Collaborative brought together a wide range of legislators, state and county officials,
- law enforcement and first responders, health care professionals and other citizens to work
- together to develop and implement a Plan to reduce prescription opioid abuse and deaths from
- overdose. The full Plan is available at: https://health.hawaii.gov/substance-
- abuse/files/2013/05/The-Hawaii-Opioid-Initiative.pdf.

1	The DOH is also grateful to the sponsors of SB 2244 SD 1 for their recommendation to
2	expand the use of the opioid informed consent template developed by the Collaborative. The
3	template is now posted on the DOH website: https://health.hawaii.gov/substance-
4	abuse/files/2017/12/opioid_informed_consent_template.pdf.
5	The DOH defers to the Department of Labor & Industrial Relations on the regulation and
6	implementation of the Hawaii State Compensation Mutual Insurance Fund.
7	Thank you for the opportunity to provide testimony.

7

DEPARTMENT OF HUMAN RESOURCES CITY AND COUNTY OF HONOLULU

650 SOUTH KING STREET, 10^{TH} FLOOR • HONOLULU, HAWAII 96813 TELEPHONE: (808) 768-8500 • FAX: (808) 768-5563 • INTERNET: www.honolulu.gov/hr

KIRK CALDWELL MAYOR



CAROLEE C. KUBO DIRECTOR

NOEL T. ONO ASSISTANT DIRECTOR

March 22, 2018

The Honorable Aaron Ling Johanson, Chair The Honorable Daniel Holt, Vice Chair and Members of the Committee on Labor & Public Employment

The Honorable John M. Mizuno, Chair The Honorable Bertrand Kobayashi, Vice Chair and Members of the Committee on Health & Human Services

The House of Representatives State Capitol, Room 309 415 South Beretania Street Honolulu, Hawaii 96813

Dear Chairs Johanson and Mizuno, Vice Chairs Holt and Kobayashi, and Members of the Committees:

SUBJECT: Senate Bill No. 2244, S.D. 1

Relating to Workers' Compensation

S.B. 2244, S.D. 1, requires health care providers in the workers' compensation system who are authorized to prescribe opioids to adopt and maintain policies for informed consent to opioid therapy in circumstances that carry elevated risk of dependency and establishes limits for concurrent opioid and benzodiazepine prescriptions.

The City and County of Honolulu, Department of Human Resources, fully supports this measure, which we believe will help to lessen the potential for abuse and possible addiction, and is consistent with providing reasonably needed medical care, services, and supplies to injured workers.

Thank you for the opportunity to testify.

Sincerely,

Carolee C. Kubo

Censu C. Kolor

Director



SB2244 SD1 Workers Comp. Opioid Informed Consent, Prescriptive Limits COMMITTEE ON LABOR & PUBLIC EMPLOYMENT:

• Representative Aaron Ling Johanson, Chair; Representative Daniel Holt, Vice Chair COMMITTEE ON HEALTH AND HUMAN SERVICES:

- Representative John Mizuno, Chair; Representative Bertrand Kobayashi, Vice Chair
- Thursday, March 22, 2018: 8:30 am
- Conference Room 309

Hawaii Substance Abuse Coalition (HSAC) Comments on SB2244 SD1:

GOOD MORNING CHAIRS, VICE CHAIRS AND DISTINGUISHED COMMITTEE MEMBERS. My name is Alan Johnson. I am the current chair of the Hawaii Substance Abuse Coalition (HSAC), a statewide organization of almost 40 alcohol and drug treatment and prevention agencies.

The Hawaii Opioid Action Plan (HOAP), the collaborative gathering of about 150 political, government, insurers and providers, including HSAC members, developed plans that included our construction of a formal opioid consent form.

- We recommend limits for overall excessive use but let's be careful to allow doctors room for medical necessity, especially for serious conditions.
- We defer to HMA and WIMAH (medical healthcare practitioners) for input in this area.
- Also, we defer to regulatory bodies for what may have to change to facilitate good implementation of this proposed legislation.

We (HOAP) came together with so many, accomplishing so much in a short time because we are cognizant of the impending crisis due to Hawaii's opioid misuse and high overdose.

We appreciate the opportunity to provide testimony and are available for questions.

SB-2244-SD-1

Submitted on: 3/21/2018 4:57:09 AM

Testimony for LAB on 3/22/2018 8:30:00 AM

Submitted By	Organization	Testifier Position	Present at Hearing
Melodie Aduja	Oahu County Committee on Legislative Priorities of the Democratic Party of Hawai'i	Support	No

Comments:

To the Honorable Aaron Ling Johanson, Chair; the Honorable Daniel Holt, Vice-Chair, and Members of the Committee on Labor & Public Employment:

To the Honorable John M. Mizuno, Chair; the Honorable Bertrand Kobayashi, Vice-Chair, and Members of the Committee on Health & Human Services:

Good morning. My name is Melodie Aduja. I serve as Chair of the Oahu County Committee ("OCC") Legislative Priorities Committee of the Democratic Party of Hawaii. Thank you for the opportunity to provide written testimony on **SB2244 SD1** relating to Workers' Compensation; Opioid Therapy; Informed Consent; and Prescription Limits.

The OCC Legislative Priorities Committee is in favor of **SB2244 SD1** and supports its passage.

SB2244 SD1 is in accord with the Platform of the Democratic Party of Hawai'i ("DPH"), 2016, as it requires health care providers in the workers' compensation system who are authorized to prescribe opioids to adopt and maintain policies for informed consent to opioid therapy in circumstances that carry elevated risk of dependency; and establishes limits for concurrent opioid and benzodiazepine prescriptions, effect 1/1/2045.

The DPH Platform states that "[a]ccess to health care is a basic human need. Our citizens and visitors have an inherent right to high quality, high standard health care. The state legislature and the federal government should take all appropriate steps to create and support a health care system of public, for-profit, and nonprofit hospitals and other medical facilities that follow best practices to enhance and protect and preserve life. (Platform of the DPH, P.7, Lines 361-364 (2016)).

We also support the establishment of adequate mental health and statewide drug rehabilitation programs set up in conjunction with policing policies aimed at enabling all that seek assistance to obtain whatever support assistance is needed to allow them to remain free of drug dependence. (Platform of the DPH, P.7, Lines 382-384 (2016)).

Given that **SB2244 SD1** requires health care providers in the workers' compensation system who are authorized to prescribe opioids to adopt and maintain policies for informed consent to opioid therapy in circumstances that carry elevated risk of dependency; and establishes limits for concurrent opioid and benzodiazepine prescriptions, effective 1/1/2045, it is the position of the OCC Legislative Priorities Committee to support this measure.

Thank you very much for your kind consideration.
Sincerely yours,
/s/ Melodie Aduja
Melodie Aduja, Chair, OCC Legislative Priorities Committee
Email: legislativepriorities@gmail.com, Text/Tel.: (808) 258-8889



To: Rep. Aaron Ling Johanson, Chair

Rep. Daniel Holt, Vice Chair

Members of the Committee on Labor & Public Employment

Rep. John M. Mizuno, Chair

Rep. Bertrand Kobayashi, Vice Chair

Members of the Committee on Health & Human Services

Date: Thursday, March 22, 2018

Time: 8:30 a.m.

Place: Conference Room 309

State Capitol

415 South Beretania Street

Comments on SB2244 SD1

Work Injury Medical Association of Hawaii (WIMAH) is a nonprofit trade organization of healthcare providers dedicated and devoted to promoting the best practices and policies for the injured workers of Hawaii and the providers who take care of them and to enhance the quality of life of injured workers in this community. WIMAH represents the majority of physicians treating injured workers in the State of Hawaii.

SB2244 SD1 requires health care providers in the workers' compensation system who are authorized to prescribe opioids to adopt and maintain policies for informed consent to opioid therapy in

circumstances that carry elevated risk of dependency. It also establishes limits for concurrent opioid and benzodiazepine prescriptions.

Act 66 of 2017 (originating as SB505) contained identical provisions on informed consent and prescription limits for health care providers generally. We understand that Act 66 applies to health care providers in the workers' compensation system too. Therefore, we question whether SB2244 SD1 is needed or whether it is duplicative and unnecessary. We would recommend that a legal opinion from the Attorney General's office be obtained before passing this bill.

Thank you for your consideration.

Scott J. Miscovich, MD

President and Director

SB 2244 SD-1

LATE TESTIMONY